Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258316 | 1.00 | CSNK2A1 (0.40) | CSNK2A1PDE10APDGFRACDK5TYRO3 | |
| SCHEMBL4507507 | 0.81 | GRM4 (0.43) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL31068115 | 0.81 | PDGFRA (0.39) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL29349067 | 0.81 | PDGFRA (0.39) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL30258317 | 0.80 | PDGFRA (0.41) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL20520453 | 0.80 | PDGFRA (0.41) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL20520398 | 0.80 | PDGFRA (0.38) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL30258108 | 0.80 | PDGFRA (0.38) | PDGFRACDK5TYRO3ADORA2AADORA2B | |
| SCHEMBL22122298 | 0.77 | PDGFRA (0.44) | CSNK2A1PDE10APDGFRACDK5TYRO3 | |
| SCHEMBL17673889 | 0.77 | PDGFRA (0.39) | PDGFRACDK5TYRO3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4514473-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | CSNK2A1 3594/4885PDE10A 4601/4885PDGFRA 3293/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CSNK2A1 3594/4885PDE10A 4601/4885PDGFRA 3293/4885 |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CSNK2A1 3594/4885PDE10A 4601/4885PDGFRA 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.